title: Antibody-induced transplantation tolerance: the role of dominant regulation.
abstract: A short-treatment with nondepleting antibodies, such as those targeting CD4 or CD154 (CD40 ligand), allows long-term graft survival without the need for continuous immunosuppression. This state of immune tolerance is maintained by regulatory CD4+ T cells present within both the lymphoid tissue and the tolerated graft. The nature of such regulatory T cells, their relationship to CD4+CD25+ T cells, and their mode of action have all been the subjects of much attention recently. Here, we review recent progress on understanding the nature, specificity, and mechanisms of action of T cells mediating dominant tolerance brought about by antibody therapy.
authors.affiliation: Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK. luis.graca@pathology.oxford.ac.uk
authors.forename: Luis
authors.initials: L
authors.lastname: Graca
authors.forename: Alain
authors.initials: A
authors.lastname: Le Moine
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Cobbold
authors.forename: Herman
authors.initials: H
authors.lastname: Waldmann
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D051379:Mice; D051381:Rats; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2